{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:34:10Z","timestamp":1776288850048,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13555-023-01095-8","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:02:18Z","timestamp":1705683738000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Adverse Events Associated with Encapsulated Benzoyl Peroxide\/Tretinoin, 3%\/0.1%, and Encapsulated Benzoyl Peroxide, 5%"],"prefix":"10.1007","volume":"14","author":[{"given":"Amy","family":"Poteate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofra","family":"Levy-Hacham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-7298","authenticated-orcid":false,"given":"J. P.","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"5","key":"1095_CR1","first-page":"36","volume":"15","author":"LJ Green","year":"2022","unstructured":"Green LJ, Lain E, Prunty T, Rhoades R. Enhancing topical pharmacotherapy for acne and rosacea: vehicle choices and outcomes. J Clin Aesthet Dermatol. 2022;15(5):36\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jcis.2020.06.114","volume":"579","author":"M Erlich","year":"2020","unstructured":"Erlich M, Arie T, Koifman N, Talmon Y. Structure elucidation of silica-based core-shell microencapsulated drugs for topical applications by cryogenic scanning electron microscopy. J Colloid Interface Sci. 2020;579:778\u201385.","journal-title":"J Colloid Interface Sci"},{"issue":"14","key":"1095_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMcp1702493","volume":"379","author":"AL Zaenglein","year":"2018","unstructured":"Zaenglein AL. Acne vulgaris. N Engl J Med. 2018;379(14):1343\u201352. https:\/\/doi.org\/10.1056\/NEJMcp1702493.","journal-title":"N Engl J Med"},{"issue":"8","key":"1095_CR4","first-page":"475","volume":"100","author":"LK Oge","year":"2019","unstructured":"Oge LK, Broussard A, Marshall MD. Acne vulgaris: diagnosis and treatment. Am Fam Physician. 2019;100(8):475\u201384.","journal-title":"Am Fam Physician"},{"issue":"suppl 2","key":"1095_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.15043","volume":"32","author":"B Dr\u00e9no","year":"2018","unstructured":"Dr\u00e9no B, P\u00e9castaings S, Corvec S, Veraldi S, Khammari A, Roques C. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(suppl 2):5\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1095_CR6","first-page":"185","volume":"32","author":"LF Montes","year":"1983","unstructured":"Montes LF, Cordero AA, Kriner J, Loder J, Flanagan AD. Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis. 1983;32(2):185\u201390.","journal-title":"Cutis"},{"key":"1095_CR7","unstructured":"Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%\/clindamycin 1% topical gel with vehicle in the treatment of rosacea.\u00a0Cutis. 2004;73(6)(Suppl):11\u20137."},{"issue":"5","key":"1095_CR8","first-page":"26","volume":"16","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Kwong P, Draelos Z, et al. Impact of topical vehicles and cutaneous delivery technologies on patient adherence and treatment outcomes in acne and rosacea. J Clin Aesthet Dermatol. 2023;16(5):26\u201334.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"1095_CR9","first-page":"s17","volume":"10","author":"LH Kircik","year":"2011","unstructured":"Kircik LH. Importance of vehicles in acne therapy. J Drugs Dermatol. 2011;10(6):s17\u201323.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1095_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u2013973.e33.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1095_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/cr100161x","volume":"111","author":"R Ciriminna","year":"2011","unstructured":"Ciriminna R, Sciortino M, Alonzo G, de Schrijver A, Pagliaro M. From molecules to systems: sol\u2013gel microencapsulation in silica-based materials. Chem Rev. 2011;111(2):765\u201389.","journal-title":"Chem Rev"},{"key":"1095_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.093","author":"J Del Rosso","year":"2023","unstructured":"Del Rosso J, Sugarman J, Green L, et al. Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: results from two phase\u00a03 double-blind, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.093. Accessed 14 Sep 2023.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1095_CR13","first-page":"34","volume":"16","author":"N Bhatia","year":"2023","unstructured":"Bhatia N, Werschler WP, Baldwin H, et al. Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase\u00a0III, randomized, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):34\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"1095_CR14","first-page":"27","volume":"16","author":"W Werschler","year":"2023","unstructured":"Werschler W, Sugarman J, Bhatia N, et al. Long-term efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from an extension of two phase\u00a0III, vehicle-controlled trials. J Clin Aesthet Dermatol. 2023;16(8):27\u201333.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"1095_CR15","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s13555-022-00808-9","volume":"12","author":"L Szymanski","year":"2022","unstructured":"Szymanski L, Arekapudi KL. Adverse-event reports in over-the-counter topical acne drug products containing benzoyl peroxide from a specific pharmaceutical company in the USA. Dermatol Ther (Heidelb). 2022;12(11):2397\u2013400.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1095_CR16","unstructured":"Onexton (clindamycin phosphate and benzoyl peroxide gel) [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2020."},{"key":"1095_CR17","unstructured":"Benzamycin (erythromycin-benzoyl peroxide gel) [package insert]. Berwyn, PA: Dermik Laboratories;2003."},{"key":"1095_CR18","unstructured":"Epiduo forte (adapalene and benzoyl peroxide) [package insert]. Fort Worth, Tx: Galderma Laboratories LP;2015."},{"issue":"2","key":"1095_CR19","first-page":"103","volume":"86","author":"BA Yentzer","year":"2010","unstructured":"Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103\u20138.","journal-title":"Cutis"},{"issue":"4","key":"1095_CR20","first-page":"281","volume":"82","author":"ZD Draelos","year":"2008","unstructured":"Draelos ZD, Callender V, Young C, Dhawan SS. The effect of vehicle formulation on acne medication tolerability. Cutis. 2008;82(4):281\u20134.","journal-title":"Cutis"},{"issue":"6","key":"1095_CR21","first-page":"605","volume":"10","author":"SR Feldman","year":"2011","unstructured":"Feldman SR, Chen DM. How patients experience and manage dryness and irritation from acne treatment. J Drugs Dermatol. 2011;10(6):605\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2s","key":"1095_CR22","first-page":"s100","volume":"18","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Kircik LH, Zeichner J, Stein GL. The clinical relevance and therapeutic benefit of established active ingredients incorporated into advanced foam vehicles: vehicle characteristics can influence and improve patient outcomes. J Drugs Dermatol. 2019;18(2s):s100\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"1095_CR23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3390\/pharmaceutics13122012","volume":"13","author":"TM Barnes","year":"2021","unstructured":"Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for drug delivery and cosmetic moisturizers: review and comparison. Pharmaceutics. 2021;13(12):2012.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1095_CR24","first-page":"97","volume":"11","author":"T Williamson","year":"2018","unstructured":"Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study. Am Health Drug Benefits. 2018;11(2):97\u2013106.","journal-title":"Am Health Drug Benefits"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01095-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T22:09:34Z","timestamp":1708985374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01095-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01095-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy Poteate and JP York work for Galderma. Ofra Levy-Hacham is an employee of Sol\u2013Gel Technologies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics committee approval was not required because this article only details collected pharmacovigilance data from real-world use.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}